Comparable efficacy and safety of darbepoetin alfa 200 μg every 2 weeks and epoetin alfa 40,000 U weekly in patients with breast cancer: Results of a randomized comparison

Journal of Supportive Oncology

Volumn 3, Issue 2 SUPPL. 1, 2005, Pages 30-31

  Schwartzberg, Lee ^a   Yee, Lorrin ^a   Charu, Veena ^a   Tomita, Dianne ^a   Rossi, Greg ^a   Senecal, Frank ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE;

ADULT; ANEMIA; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PATIENT SATISFACTION; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 15944424554     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Schwartzberg L, Yee L, Charu V, et al. Comparable efficacy and safety of darbepoetin alfa 200 mcg every 2 weeks (Q2W) and epoetin alfa 40,000 U weekly (QW) in patients (pts) with breast cancer: results of a randomized comparison. Poster presented at the 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, Tex. Abstract 6030.